6-TGN levels (azathioprine drug monitoring) and markers of mucosal healing in patients with inflammatory bowel disease

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

DRKS

Registry ID

DRKS00013246

Enrollment

300

Registered

2017-11-21

Start date

2017-11-10

Completion date

Unknown

Last updated

2026-04-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

K50 K51

Interventions

Group 1: Patients with IBD and azathioprine monotherapy Retrospective data analysis (6-TGN, Calprotectin, lab values, Montreal Classification, clinical disease activity)

Eligibility

Sex/Gender

All

Age

18 Years to 100 Years

Inclusion criteria

Inclusion criteria: IBD, azathioprine Therapy, values for 6-TGN and FC (max. 4 weeks apart), patients from 2009-2016

Exclusion criteria

Exclusion criteria: Steroids >20 mg, additional immunosuppressive therapy during last 3 months or currently

Design outcomes

Primary

Measure	Time frame
Correlation between 6-TGN (6-Thioguanin-Nucleotide) and fecal calprotectin; retrospective data analysis	—

Secondary

Measure	Time frame
Subgroup analysis of patients in clinical remission	—

Countries

Germany

Contacts

Public ContactOliver Bachmann

MHH OE6810

bachmann.oliver@mh-hannover.de+495115326766

Outcome results

None listed

Source: DRKS (via WHO ICTRP) · Data processed: May 1, 2026